Sign in

CIK 0001626971 · Non-accelerated filer<br>Smaller reporting company

Corvus Pharmaceuticals, Inc.

Sign in to watch
Ticker
CRVS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
464670809
Phone
(650) 900-4520
Business address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
  1. 8-K Event Executive or director change
  2. 8-K Event Regulation FD disclosure
  3. 4 Open-market buy President and CEO bought 15,008 shares at an average $3.00 ($45,029)
  4. 8-K Event Material agreement · Unregistered share sale
  5. 8-K Event Regulation FD disclosure · Other events
  6. 10-Q Report Quarterly Report
  7. 8-K Event Results of operations
  8. 4 Open-market buy Director bought 142,656 shares at $3.51 ($500,723)
  9. 4 Open-market buy Director bought 142,656 shares at $3.51 ($500,723)
  10. 4 Open-market buy President and CEO bought 7,500 shares at an average $3.56 ($26,725)
  11. SC 13G/A Stake Amended Statement of Ownership
  12. 10-Q Report Quarterly Report
  13. 8-K Event Results of operations
  14. SC 13D/A Stake Beneficial Ownership Report
  15. 4 Open-market sale 10% owner sold 1,492,956 shares at an average $4.07 ($6,077,845)
  16. SC 13D/A Stake Beneficial Ownership Report
  17. 4 Open-market buy Director bought 657,344 shares at an average $3.72 ($2,444,065)
  18. 4 Open-market buy Director bought 657,344 shares at an average $3.72 ($2,444,065)
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 18 of 30 · 584 filings